Jump to content

Tavilermide: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Yobot (talk | contribs)
Bots
4,733,870 edits
m →top: WP:CHECKWIKI error fixes/ ISSN syntax fixes using AWB (11967)
Line 5: Line 5:
| IUPAC_name = 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
| IUPAC_name = 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
| image = Tavilermide_structure.png
| image = Tavilermide_structure.png
| width =
| width =


<!--Clinical data-->
<!--Clinical data-->
Line 51: Line 51:
}}
}}


'''Tavilermide''' ([[International Nonproprietary Name|INN]]) (developmental code name '''MIM-D3''') is a selective, [[small-molecule]] [[partial agonist]] of [[TrkA]], or a [[nerve growth factor]] (NGF) [[mimetic]].<ref name="MeerovitchTorkildsen2013">{{cite journal|last1=Meerovitch|first1=Karen|last2=Torkildsen|first2=Gail|last3=Lonsdale|first3=John|last4=Goldfarb|first4=Heidi|last5=Lama|first5=Teresa|last6=Cumberlidge|first6=Garth|last7=Ousler III|first7=George W.|title=Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye|journal=Clinical Ophthalmology|year=2013|pages=1275|issn=1177-5483|doi=10.2147/OPTH.S44688}}</ref><ref name="JainLi2011">{{cite journal|last1=Jain|first1=Pooja|last2=Li|first2=Ruihong|last3=Lama|first3=Teresa|last4=Saragovi|first4=H. Uri|last5=Cumberlidge|first5=Garth|last6=Meerovitch|first6=Karen|title=An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye|journal=Experimental Eye Research|volume=93|issue=4|year=2011|pages=503–512|issn=00144835|doi=10.1016/j.exer.2011.06.014}}</ref><ref name="VickersGupta2015">{{cite journal|last1=Vickers|first1=Laura A.|last2=Gupta|first2=Preeya K.|title=The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline|journal=Ophthalmology and Therapy|year=2015|issn=2193-8245|doi=10.1007/s40123-015-0038-y}}</ref> It was under development by [[Mimetogen Pharmaceuticals]] as an [[ophthalmic solution|ophthalmic (eye drop) solution]] for the treatment of [[dry eyes]], and reached [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for this indication. Tavilermide is currently being evaluated in two multi-center Phase 3 clinical studies in the United States for the treatment of dry eye disease.[http://www.streetinsider.com/Corporate+News/Allergan+%28AGN%29,+Mimetogen+Pharma+Enter+MIM-D3+D+Development+Collaboration/11033405.html] Tavilermide is also in [[Phases of clinical research#Phase I|phase I]] clinical trials for the treatment of [[glaucoma]]; studies are ongoing.<ref name="pmid22349567">{{cite journal | vauthors = Chang EE, Goldberg JL | title = Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement | journal = Ophthalmology | volume = 119 | issue = 5 | pages = 979–86 | year = 2012 | pmid = 22349567 | pmc = 3343191 | doi = 10.1016/j.ophtha.2011.11.003 | url = }}</ref>[http://adisinsight.springer.com/drugs/800033231]
'''Tavilermide''' ([[International Nonproprietary Name|INN]]) (developmental code name '''MIM-D3''') is a selective, [[small-molecule]] [[partial agonist]] of [[TrkA]], or a [[nerve growth factor]] (NGF) [[mimetic]].<ref name="MeerovitchTorkildsen2013">{{cite journal|last1=Meerovitch|first1=Karen|last2=Torkildsen|first2=Gail|last3=Lonsdale|first3=John|last4=Goldfarb|first4=Heidi|last5=Lama|first5=Teresa|last6=Cumberlidge|first6=Garth|last7=Ousler III|first7=George W.|title=Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye|journal=Clinical Ophthalmology|year=2013|pages=1275|issn=1177-5483|doi=10.2147/OPTH.S44688}}</ref><ref name="JainLi2011">{{cite journal|last1=Jain|first1=Pooja|last2=Li|first2=Ruihong|last3=Lama|first3=Teresa|last4=Saragovi|first4=H. Uri|last5=Cumberlidge|first5=Garth|last6=Meerovitch|first6=Karen|title=An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye|journal=Experimental Eye Research|volume=93|issue=4|year=2011|pages=503–512|issn=0014-4835|doi=10.1016/j.exer.2011.06.014}}</ref><ref name="VickersGupta2015">{{cite journal|last1=Vickers|first1=Laura A.|last2=Gupta|first2=Preeya K.|title=The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline|journal=Ophthalmology and Therapy|year=2015|issn=2193-8245|doi=10.1007/s40123-015-0038-y}}</ref> It was under development by [[Mimetogen Pharmaceuticals]] as an [[ophthalmic solution|ophthalmic (eye drop) solution]] for the treatment of [[dry eyes]], and reached [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for this indication. Tavilermide is currently being evaluated in two multi-center Phase 3 clinical studies in the United States for the treatment of dry eye disease.[http://www.streetinsider.com/Corporate+News/Allergan+%28AGN%29,+Mimetogen+Pharma+Enter+MIM-D3+D+Development+Collaboration/11033405.html] Tavilermide is also in [[Phases of clinical research#Phase I|phase I]] clinical trials for the treatment of [[glaucoma]]; studies are ongoing.<ref name="pmid22349567">{{cite journal | vauthors = Chang EE, Goldberg JL | title = Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement | journal = Ophthalmology | volume = 119 | issue = 5 | pages = 979–86 | year = 2012 | pmid = 22349567 | pmc = 3343191 | doi = 10.1016/j.ophtha.2011.11.003 | url = }}</ref>[http://adisinsight.springer.com/drugs/800033231]


==See also==
==See also==

Revision as of 17:16, 9 March 2016

Tavilermide
Clinical data
Routes of
administration		Eye drop
ATC code
  • None
Identifiers
  • 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H32N6O11
Molar mass580.54448 g/mol g·mol−1
3D model (JSmol)
  • C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)NC(C(=O)NC(C(=O)NC1C(=O)NCC(=O)O)CCCCN)CCC(=O)O

Tavilermide (INN) (developmental code name MIM-D3) is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.[1][2][3] It was under development by Mimetogen Pharmaceuticals as an ophthalmic (eye drop) solution for the treatment of dry eyes, and reached phase III clinical trials for this indication. Tavilermide is currently being evaluated in two multi-center Phase 3 clinical studies in the United States for the treatment of dry eye disease.[1] Tavilermide is also in phase I clinical trials for the treatment of glaucoma; studies are ongoing.[4][2]

See also

References

  1. ^ Meerovitch, Karen; Torkildsen, Gail; Lonsdale, John; Goldfarb, Heidi; Lama, Teresa; Cumberlidge, Garth; Ousler III, George W. (2013). "Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye". Clinical Ophthalmology: 1275. doi:10.2147/OPTH.S44688. ISSN 1177-5483.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  2. ^ Jain, Pooja; Li, Ruihong; Lama, Teresa; Saragovi, H. Uri; Cumberlidge, Garth; Meerovitch, Karen (2011). "An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye". Experimental Eye Research. 93 (4): 503–512. doi:10.1016/j.exer.2011.06.014. ISSN 0014-4835.
  3. ^ Vickers, Laura A.; Gupta, Preeya K. (2015). "The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline". Ophthalmology and Therapy. doi:10.1007/s40123-015-0038-y. ISSN 2193-8245.
  4. ^ Chang EE, Goldberg JL (2012). "Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement". Ophthalmology. 119 (5): 979–86. doi:10.1016/j.ophtha.2011.11.003. PMC 3343191. PMID 22349567.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Tavilermide&oldid=709196391"